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Abstract
The heart-specific isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB2) is 
an important regulator of glycolytic flux in cardiac cells. Here, we present the crystal structures of 
two PFKFB2 orthologues, human and bovine, at resolutions of 2.0 and 1.8Å, respectively. Citrate, 
a TCA cycle intermediate and well-known inhibitor of PFKFB2, co-crystallized in the 2-kinase 
domains of both orthologues, occupying the fructose-6-phosphate binding-site and extending into 
the γ-phosphate binding pocket of ATP. This steric and electrostatic occlusion of the γ-phosphate 
site by citrate proved highly consequential to the binding of co-complexed ATP analogues. The 
bovine structure, which co-crystallized with ADP, closely resembled the overall structure of other 
PFKFB isoforms, with ADP mimicking the catalytic binding mode of ATP. The human structure, 
on the other hand, co-complexed with AMPPNP, which, unlike ADP, contains a γ-phosphate. The 
presence of this γ-phosphate made adoption of the catalytic ATP binding mode impossible for 
AMPPNP, forcing the analogue to bind atypically with concomitant conformational changes to the 
ATP binding-pocket. Inhibition kinetics were used to validate the structural observations, 
confirming citrate’s inhibition mechanism as competitive for F6P and noncompetitive for ATP. 
Together, these structural and kinetic data establish a molecular basis for citrate’s negative feed-
back loop of the glycolytic pathway via PFKFB2.
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The bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB), 
catalyzes both the synthesis and hydrolysis of fructose-2,6-bisphosphate (Fru-2,6-P2) as a 
functional homodimer (C. Wu et al. 2006). The dual enzymatic activities are provided by the 
two separate catalytic domains existing in a single protein subunit, to control the 
concentration of Fru-2,6-P2, the most potent allosteric activator of 6-phosphofructo-1-kinase 
(PFK), the rate-limiting enzyme of glycolysis (El-Maghrabi and Pilkis 1984; Pilkis and 
Granner 1992; Pilkis et al. 1995). An elevated cellular concentration of Fru-2,6-P2 increases 
glycolytic flux, whereas a lowered concentration of Fru-2,6-P2 decreases glycolysis. 
Reflecting the diversity of tissues and their physiological functions, different tissue-specific 
isoforms of PFKFB from four distinct genes (pfkfb1-4) are expressed, each with different 
kinetic properties, and a single isoform generally predominates in each tissue: PFKFB1, the 
liver form; PFKFB2, the heart form; PFKFB3, the inducible form; and PFKFB4, the testis 
form (Okar et al. 2001).
Because of the uniqueness in its structure/function relationships, the PFKFB enzyme system 
has long been the target of structure/function studies. As a result, a significant amount of 
functional data has been produced and the crystal structures of the rat liver Fru-2,6-P2ase 
domain, the rat testis form (PFKFB4), the human liver form (PFKFB1), and human cancer 
form (PFKFB3) have been determined (Hasemann et al. 1996; Kim et al. 2006; Y. H. Lee et 
al. 2003). These data altogether allowed us to understand the molecular mechanism of 
catalytic reactions and regulation of this enzyme system. Some are now serving as a 
molecular foundation for development of therapeutics for diabetes and cancer (Garber 2004; 
A. Minchenko et al. 2002).
However, one of the most fundamental questions yet to be answered about this enzyme 
system is how each PFKFB isoform performs its differential function in hosting tissues that 
have specific physiological roles and, accordingly, different optimum conditions for glucose 
metabolism. Reflecting such differences, the PFKFB isozymes have been shown to have 
different kinetic properties, as summarized in Figure 4.5. These kinetic differences suggest 
that glucose metabolism is uniquely related to the physiological roles of the given tissues 
and not just a simple housekeeping function for energy production (Y. H. Lee et al. 2003; 
Pilkis et al. 1995).
As an effort to address the tissue-type specifically differentiated structure/function 
relationships of PFKFB isoforms, we determined the crystal structures of heart isoforms of 
PFFKB, PFKFB2, from both H. sapiens and B. taurus. Analysis of their structures and 
kinetics in comparison with those already known from the previous PFKFB studies 
suggested a regulatory mechanism as yet unknown and we introduce the results here.
Materials and Methods
Crystallization of PFKFB2 Homologs
DNA sequences encoding full length constructs of the human and bovine PFKFB2 isoforms 
were cloned into a pET-3a vector (Novagen) allowing fusions to a 6xHis tag sequence at the 
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N-termini. Both proteins were overexpressed in Escherichia coli BL21 C41(DE3) using 
0.3mM IPTG at 18°C and purified using Ni-NTA affinity columns in conjunction with SP 
Sepharose cation exchange columns. Following purification by SP Sepharose, the proteins 
were dialyzed with pH 8.0 20 mM Tris•HCl, 10 mM NaPi, 5 mM β-Mercaptoethanol, and 
5% glycerol and then concentrated to 8.0 mg/ml with Millipore centrifugal filter 
concentrators. Crystallization of the bovine PFKFB2 (bPFKFB2) were prepared via sitting 
drop vapor diffusion using a 1:1 mixture of protein sample to a mother liquor, pH 7.5 
100mM HEPES, pH 7.0 0.5% tacsimate, 13–16% polyethylene glycol 3350, and 3% 
dioxane. The crystals were grown to a dimension of 0.2 × 0.2 × 0.05 mm within 2–3 weeks 
of incubation at 20°C. Crystals of the human PFKFB2 (hPFKFB2) were also prepared with 
the sitting drop vapor diffusion method using a mother liquor, pH 6.0 100mM MES, 0.5–
3.0% polyethylene glycol 8000, 13–16% polyethylene glycol 3350, and 3% dioxane. Data 
quality crystals of hPFKFB2 were grown after 3–5 weeks of incubation at 12°C.
Data Collection and Processing
The crystals were soaked for cryo-protection and liganding in cryoprotectant solutions, 
containing the aimed ligands, for 0.5 to 2 hours prior to flash freezing at 77K using liquid 
N2. All cryoprotectant solutions were prepared by enriching the reservoir solution of each 
crystal with 35% ethylene glycol. The diffraction data was collected at both beamline 6C of 
the Pohang Accelerator Laboratory, Pohang, Korea, using the CCD detector Quantum 210 
(ADSC) with a source wavelength of 1.23986 Å or at the Gulf Coast Consortium Protein 
Crystallography Beamline (PX1) in the Center for Advanced Microstructures and Devices 
(CAMD), Louisiana State University, Baton Rouge, LA., using a Mar 165 mm CCD detector 
with a source wavelength of 1.3808 Å. All diffraction data was processed and scaled using 
HKL2000.
Crystals of hPFKFB2 belong to the primitive orthorhombic space group P212121, having 
unit cell dimensions of a = 106.5 Å, b = 113.9 Å, c = 133.2 Å and an asymmetric unit 
consisting of two monomers. Crystals of bPFKFB2 belong to the C-centered orthorhombic 
space group, C2221, with unit cell dimensions being a = 82.1 Å, b = 169.5 Å, c = 85.3 Å, α 
=90, β =90, γ =90 and an asymmetric unit consisting of one monomer. Statistics of the 
reflection data are summarized in Table 1.
Structure determination and refinement
The structures of hPFKFB2 and bPFKFB2 were determined by molecular replacement using 
the Phaser software module implemented in the PHENIX program suite. Initial models for 
both orthologues were determined using the human liver PFKFB (1K6M) as a search model 
(Y. H. Lee et al. 2003). The final structures were achieved after iterated model rebuilding 
and refinement using PHENIX and Coot (P. D. Adams et al. 2010; Emsley and Cowtan 
2004). The Rcrys/Rfree of the final models are 0.202/0.225 and 0.156/0.211 for hPFKFB2 
and bPFKFB2, respectively.
The final models revealed the residues 31–450 out of 505 of hPFKFB2 and those of 28–450 
of bPFKFB2. The missing residues are all from both the N- and C-terminal regulatory 
domains and are considered disordered, based on the results from mass spectroscopy of melt 
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crystals (data not shown). For the human model, 93.2% of the 420 revealed residues lie 
within the ‘most favorable region’ of the main chain dihedral angle distribution, whereas 
none are found in the ‘disallowed region’. Similarly, for the 423 residues of the bovine 
orthologue, 90.9% are within the “most favorable region” and none are in the “disallowed 
region”.
Biochemical Assays
The 2-kinase inhibition assays were performed using a Fru-2,6-P2 assay modified for 96-
well plates from the conventional method for both the wildtype hPFKFB2 and Y428A 
mutant (Van Schaftingen E, et al.). This assay consisted of two sequential steps: Fru-2,6-P2 
production by PFKFB2 and allosteric activation of PFK-1 by the produced Fru-2,6-P2. For 
the first reaction, Fru-2,6-P2 synthesis by PFKFB2, was started by adding 130 nM PFKFB2 
to mixtures containing 20 mM pH 8.0 TES, 1 mM DTT, 2 mM MgCl2, 0.5% tween, and 
varying concentrations of citrate, ATP and Fru-6-P, ranging from 0 to 200 mM for each. This 
reaction was allowed to run for 10 minutes at 25°C and then stopped by the addition of 0.1 
M KOH. Aliquots of 1–4 μL of the first reaction were transferred, after pH neutralization, to 
the reactions of the second step, which consisted of 50 mM pH 8.0 Tris•HCl, 0.2 mM 
NADH, 5 mM DTT, 1 mM F-6-P, 2 mM MgCl2, 0.70 units/mL Aldolase, 0.45 units/mL 
glyceraldehyde dehydrogenase, 0.60 units/mL triose-phosphate isomerase, and 10 mU 
pyrophosphate-dependent phosphofructokinase. The reactions of second step were started by 
adding 0.5 mM sodium pyrophosphate and were then measured for changes in absorbance at 
340 nm over a period of 30 minutes.
Accession numbers
Protein Data Bank: Coordinates and structure factors were deposited with the following 
codes: H5R5 (Bovine PFKFB2) and 5HTK (Human PFKFB2).
Results and Discussion
Overall Structures of PFKFB2
As summarized in the previous section and Table 1, crystal structures of the two PFKFB2 
orthologs were determined – human (hPFKFB2) to 2.0Å and bovine (bPFKFB2) to 1.8Å – 
to elucidate any structural/functional differences in heart-type PFKFB compared to other 
isoforms. Similar to the other PFKFB isoforms, the crystal structure of the heart isozyme, 
for both human and bovine orthologues, shows a PFKFB-typical head-to-head homodimer 
arrangement (Figure 1a) with a dimeric interface constituted primarily through crystal 
contacts made between two kinase domains.
Each PFKFB2 monomer consists of a single polypeptide chain that can be subdivided into 
four distinct regions: the 6-phosphofructo-2-kinase (2-Kase) domain, the fructose-2,6-
bisphosphatase (2-Pase) domain, and two regulatory domains. The two catalytic domains are 
conserved among the different tissue isoforms with the sequence identity 76–83%, whereas 
the N-terminal and C-terminal domains are highly variable. Among 505 amino acid residues 
of PFKFB2, residues 1–37 and 451–505 constitute the N- and C-terminal regulatory 
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domains, whereas residues 38–248 and 249–450 constitute the 2-Kase and 2-Pase domains, 
respectively.
The sequence identity shared between the human and bovine orthologs is larger than 95%, 
supporting the notion that the two PFKFB2 orthologs play a physiological role common to 
both human and swine. To analyze the structural differences between the two orthologs, Cα 
traces of hPFKFB2’s 2-Kase and 2-Pase domains were superimposed, separately, onto 
corresponding domains of bPFKFB2 (Figure 1b). It was not appropriate to compare the two 
domains together, because differences in liganding states of the orthologs cause differences 
in the domain-domain interface. In agreement with the high sequence identity, the two 
catalytic domains showed a high degree of overall similarity, with RMSD values of 1.46 Å 
and 0.68 Å, for the 2-Kase and 2-Pase domains, respectively. Although the discrepancy in 
the 2-Kase domains is higher than expected, no significant structural differences between the 
two orthologs, which would implicate coinciding differences in the structure/function 
relationship, are apparent.
The unexpectedly high RMSD for the 2-Kase domains is likely due to differences in 
liganding states of the two orthologs despite sharing similar liganding conditions during 
crystallization. For both the structures, Fru-6-P and citrate were in common, whereas 
AMPPNP – a non-hydrolyzable ATP analog – and ADP were exclusively included fill the 
ATP pockets of hPFKFB2 and bPFKFB2, respectively. Structural dissimilarities were 
concentrated to localized regions within-or-near the 2-Kase’s active site and correlate with 
citrate’s binding to the 2-Kase domain. Despite Fru-6-P being present in crystallization 
conditions for both orthologues, it didn’t complex with the 2-kinase domain of either, 
regardless of concentration. Instead, citrate, from an earlier purification step, occupies the 
Fru-6-P binding pocket. Interestingly, the binding of citrate appears to significantly 
influence ATP but not ADP binding to the 2-Kase domain. The details will be discussed in 
the following sections.
As indicated in Table 1, His258 were found as phosphorylated histidine in both the 
structures despite the fact that no Fru-2,6-P2 was involved in crystallization attempts. No 
other isoforms have shown phosphorylated histidine unless the crystals are soaked with high 
concentrations of Fru-2,6-P2 to induce the phosphorylated histidine as a catalytic 
intermediate state (Kim et al. 2007). The only possibility is that the phosphorylated histidine 
was formed by Fru-2,6-P2 synthesized during the PFKFB2 expression in E. coli. In addition, 
it has to be presumed that PFKFB2 has the phosphor-histidine state, which is more stable 
than that of any other isoforms.
Citrate binding to the 2-Kase domain
There was no Fru-6-P molecule bound to the 2-Kinase domain despite being present in the 
crystallization mixture, because the 2-Kase, which follows an ordered reaction, requires ATP 
binding prior to Fru-6-P binding. Instead, citrate was found to be bound to the Fru-6-P 
pocket of the 2-Kase domains of both hPFKFB2 and bPFKFB2 with strong hydrogen bonds 
to Thr130 and Tyr197 and salt bridges with Arg78 and Arg102 (Figure 2a). Except for 
Arg102, which is conserved though, all of these residues are known to be involved in the 
catalytic binding of Fru-6-P to the 2-Kase domain. This binding mode of citrate is conserved 
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between the bovine and human orthologs. It is known that the 2-Kase of PFKFB2, the heart 
isoform, is very sensitive to inhibition from products of TCA cycle such as succinate and 
citrate. A previous structural study has suggested that succinate behaves like a competitive 
inhibitor against Fru-6-P (Galluzzi et al. 2013).
However, citrate bound to PFKFB2 suggests an inhibition pattern, which is different from 
that of succinate, which was previously studied (Yuen et al. 1999). While primarily located 
in the Fru-6-P binding site, citrate, unlike succinate, impedes the γ-phosphate of AMPPNP 
from occupying its normal location for the Fru-2,6-P2 synthesis. When citrate from 
hPFKFB2 was superimposed onto a pseudo-Michaelis complex of PFKFB3 (2DWP), one of 
the three carboxy group arms of citrate is only 1.2Å away from the γ-phosphate of 
AMPPCP (Figure 2b) (Kim et al. 2007). Such close proximity of two negatively charged 
acidic groups is both sterically and electrostatically unfavorable for ATP binding but ADP 
binding is not significantly influenced. Thus, it has been suggested that ATP binding to the 
2-Kase domain in the known catalytic mode is not favored in the presence of citrate. And, 
considering perfect conservation of all the residues for citrate, binding of citrate to the four 
PFKFB isoforms would be very similar.
Conserved catalytic binding of ATP and ADP to the 2-Kase domain
Both hPFKFB2 and bPFKFB2 were co-crystallized in the presence of ADP and AMPPNP, 
respectively. As expected, the binding of ADP in the bPFKFB2 structure is analogous to the 
catalytic mode of ADP and ATP, which were well characterized and elucidated in previous 
studies of the PFKFB protein system (Figure 3a) (Kim et al. 2007; Y. H. Lee et al. 2003). 
The adenine moiety resides in a partly solvent-exposed hydrophobic pocket stabilized 
primarily through CH-π contributions made by Gly51, Tyr54, and Val221. A single 
hydrogen bond is formed between the adenine N6 and the Oδ of Asn168. The nucleotide 
diphosphates, on the other hand, occupy a highly anionic phosphate binding loop created by 
a Walker A motif – conserved as -49GLPARGKT56- in all PFKFB isoforms (Walker et al. 
1982). Additional hydrogen bonds to the phosphate moieties are contributed from the side 
chains of Lys172 and Tyr428. This binding is well conserved among all PFKFB isoforms. 
However, Tyr428 plays a different role upon binding of AMPPNP in the presence of citrate 
bound to 2-Kase.
An alternative ATP binding mode to the 2-Kase domain caused by citrate binding
Surprisingly, the binding mode of AMPPNP in the presence of citrate is markedly different 
from the conventional mode of catalytic ATP binding for the Fru-2,6-P2 synthesis, when it 
was revealed by the |Fo| - |Fc| omit map (Figure 3c). When AMPPNP from the 
hPFKFB2•AMPPNP complex was superimposed onto ADP of bPFKFB2•ADP complex, as 
can be seen in Figure 3b, the ribose and adenine rings of AMPPNP are rotated 115° and 
180°, respectively, relative to those of ADP. Furthermore, the centroid of AMPPNP’s 
adenine ring is 14Å shifted outward from that of ADP. Consequently, few molecular 
interactions are shared among the bindings of adenosine moieties of AMPPNP and ADP to 
PFKFB2 and, thus, the nucleoside binding sites for AMPPNP are remarkably different from 
that of ADP (Figure 3c). From the AMPPNP-complexed structure, it can be seen that the α-
carbon of Pro176 shifts ~3.3Å, placing the residue’s R-group perpendicular to AMPPNP’s 
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planar ring, allowing for CH-π contributions. More significant contributions come by way of 
π-π stacking interactions with the phenol side chain of Tyr428, which is otherwise involved 
in interaction with the phosphate moieties. For the π-π stacking between the adenine ring 
and Tyr428, the β-hairpin containing Tyr428 shifted 4Å and the phenol sidechain rotated 
away from the position for its conventional interaction with the α-phosphate moiety of ADP 
(Figure 3d).
As a consequence, the γ-phosphate of AMPNP occupies the site for the β-phosphate of 
ADP or catalytic ATP, sharing many contact residues with the α- and β-phosphates of ADP. 
Of the five residues forming the Walker A motif, Tyr54 is the only notable absence. As for 
sidechain interactions, the phosphate stabilizing hydrogen bond of Tyr428 is replaced by 
Ser174. Interactions with Lys172, on the other hand, are completely lost, with the residue 
flipping outward towards the solvent. This atypical binding of AMPPNP is inappropriate for 
the 2-Kase catalytic reaction and appeared to be caused by the citrate binding to 2-Kase as 
described in the following section.
Citrate inhibition at the active site of the 2-Kinase domain
Although previous studies have reported citrate to inhibit PFKFB enzymes, particularly the 
heart isotype, the inhibition mechanism has remained unknown (Ros and Schulze 2013). 
From the human structure of PFKFB2 presented here, it can now be seen that citrate 
competitively blocks F6P binding while simultaneously prohibiting ATP, or any γ-phosphate 
containing analogues, from binding in a catalytically active position. Inhibition studies were 
conducted to validate these structural observations. Non-linear regression analyses of the 
data supported the structural findings, showing citrate to act as a competitive inhibitor for 
F6P with a Ki of 80.3±6.5μM and non-competitive inhibitor for ATP with a Kis of 
50.23±8.0μM and Kii of 58.75±9.9μM, as shown in the double-reciprocal plot (Figure 4) and 
summarized in Table 2. It was well accepted that PFKFB3 catalyzes the reaction of Fru-2,6-
P2 synthesis with ordered bindings of ATP first and then Fru-6-P. Because citrate can bind to 
both the free enzyme (E) and the ATP bound enzyme (E•ATP), citrate is a non-competitive 
inhibitor. The noncompetitive inhibition agrees with the observation that citrate influences 
but does not completely block ATP from binding.
To validate biological significance of the citrate binding and the consequentially altered 
binding of ATP, a site-directed mutant, Y428A, the π-π stack provider for the altered ATP 
binding mode was mutated to alanine, was prepared and its kinetic properties were analyzed 
in comparison to the wild-type, as shown in Table 2. The Y428A mutant PFKFB2 exhibited 
kinetic properties, which are uniquely different from those of the wild type. Although the 
change in Km for ATP is modest, a 6-fold increase in its affinity for Fru-6-P and a near 10-
fold increase in its kcat were observed. The activity increase was probably driven by an 
increased affinity for Fru6-P, although a notable 20-fold increase in affinity for the inhibitor, 
citrate, from 50.2 μM to 2.4 μM was also observed as counteract. This difference is likely 
attributable to a reduction in the non-catalytic, inhibitory binding of ATP in response to the 
lost π-π stacking interactions between phenyl ring and the adenine base of the inhibitory 
ATP binding.
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The apparent differences in kinetic properties between wild-type and the mutant strongly 
suggest that Tyr428 makes significant contributions to citrate inhibition of 2-Kase by 
allowing ATP to bind in a non-catalytic, inhibitory fashion. As a consequence, citrate is not 
only an apparent competitive inhibitor against Fru-6-P but also makes ATP act as an 
apparent inhibitor. The present study suggests that the inhibitory ATP binding significantly 
depends on Tyr428 mediated π-π stack interactions between the adenine base moiety of 
ATP and the tyrosine side chain. When these π-π stacking interactions were prevented, as 
with the Y428A mutant, the inhibitory binding of ATP was decreased, making the overall 
inhibition potency of citrate weaker. In addition, it is likely that the mutant have a difference 
in the conformational change required for ordered bindings of ATP and Fru-6-P, because 
Tyr428 is an important residue for ATP binding. As consequence, the Fru-6-P pocket is more 
stable such that bindings of both Fru-6-P and citrate are increased as manifested in their Km 
and Ki, respectively.
The suggested model is in agreement with the previously accepted model of energy 
metabolism within cardiac cells. It has been well established that the heart cells depend 
mainly on oxidation of fatty acids and ketone bodies as energy source and that glycolysis is 
mostly down regulated in the heart through the so called “glucose-sparing effect”. This 
suggests a possible model of the glucose-sparing effect. An unnecessary increase in the 
myocardial levels of Fru-2,6-P2, the most potent allosteric activator of the glycolysis rate-
regulator protein, phosphofructokinase, is avoided by the citrate-sensitive 2-Kase domain in 
PFKFB2 isoform.
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• Solved the crystal structure of PFKFB2.
• Structurally determined the molecular basis for citrate’s inhibition of 
PFKFB2.
• Validated citrate’s inhibition model using enzyme kinetics.
• Demonstrated that citrate binding induces ATP to bind in a non-
catalytic, inhibitory fashion.
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Dimeric arrangement of heart form and a comparison of the structures of the human and 
bovine orthologues. (A) Head-to-head homodimer arrangement of the human PFKFB2. 
Shown in gray is a complete monomer, while the red and blue colors depict the 2-Kase and 
2-Pase domains, respectively. Ligands are colored by element and are shown in stick form. 
(B) Superimposed C-alpha traces of bovine (blue) and human (light gray) kinase and 
phosphatase domains. The phosphatase domains contain Fru-6-P from the bovine orthologue 
in the F-2,6-P2 binding site. The kinase domains with ADP and Citrate from the bovine 
orthologue in the ATP and F6P binding sites, respectively.
Crochet et al. Page 11














Citrate binding in the 2-Kase domain. (A) Superimposed structures of the citrate binding 
pocket for human (blue) and bovine (light gray) orthologues. Residues forming interactions 
with citrate are represented as sticks, with a ribbon diagram representing the mainchain. 
Human PFKFB2 is depicted as a blue ribbon with sticks containing green carbon atoms. In 
contrast, bovine PFKFB2 is represented as a light gray ribbon with sticks containing white 
carbon atoms. (B) AMPPCP and F6P from PFKFB3 (2DWP) overlaid onto the citrate 
binding site of human PFKFB2. The distance between the carboxy arm from citrate and 
nearest atom from the overlaid AMPPCP is shown. Both AMPPCP and F6P are semi-
transparent colored orange.
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Ligand Binding within the 2-Kase Domain. (A) Bovine PFKFB2 complexed with ADP and 
Citrate. Superimposed are AMPPCP and F6P from the pseudo-substrate complex with 
PFKFB3 (2DWP), showing the catalytic ATP and F6P binding modes, respectively. (B) 
Human PFKFB2 complexed with AMPPNP and Citrate. Superimposed are AMPPCP and 
F6P from the pseudo-substrate complex with PFKFB3 (2DWP), showing the catalytic ATP 
and F6P binding modes, respectively. (C) Unbiased Fo-Fc omit map of AMPPNP and 
neighboring residues in human PFKFB2. Contoured at 3.0σ (D) Ribbon diagram view of 
human PFKFB2 (blue) super-imposed onto the bovine orthologue (light gray). The 
sidechains and their positional differences are shown for residues involved in AMPPNP 
binding.
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2-Kase inhibition by Citrate. (A) Double reciprocal plot with F6P as the variable substrate 
showing competitive inhibition, where v=Vmax[S]/{Km(1+[I]/Kis)+[S]} (B) Double 
reciprocal plot with ATP as the variable substrate showing non-competitive inhibition, where 
v=Vmax[S]/{Km(1+[I]/Kis)+[S](1+[I]/Kii)}.
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